Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation
Keshav Gopal, Qutuba G. Karwi, Seyed Amirhossein Tabatabaei Dakhili, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 23

Showing 23 citing articles:

Redefining Diabetic Cardiomyopathy: Perturbations in Substrate Metabolism at the Heart of its Pathology
Lisa C. Heather, Keshav Gopal, Nikola Srnic, et al.
Diabetes (2024) Vol. 73, Iss. 5, pp. 659-670
Closed Access | Times Cited: 15
Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial
James L. Januzzi, Stefano Del Prato, Julio Rosenstock, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy
James L. Januzzi, Javed Butler, Stefano Del Prato, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 2, pp. 137-148
Closed Access | Times Cited: 8
Aldose reductase with quinolone antibiotics interaction: In vitro and in silico approach of its relationship with diabetic complications
Cüneyt Türkeş
Archives of Biochemistry and Biophysics (2024), pp. 110161-110161
Closed Access | Times Cited: 7
Energy metabolism: A critical target of cardiovascular injury
Qiyang Li, Shangzu Zhang, Gengqiang Yang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115271-115271
Open Access | Times Cited: 14
Alleviation of albumin glycation-induced diabetic cardiomyopathy by L-Arginine: Insights into Nrf-2 signaling
Muskan R. Thakur, Sampada S. Nachane, Rashmi S. Tupe
International Journal of Biological Macromolecules (2024) Vol. 264, pp. 130478-130478
Closed Access | Times Cited: 4
Macrod1 suppresses diabetic cardiomyopathy via regulating PARP1-NAD+-SIRT3 pathway
Yuting Liu, Hong-liang Qiu, Hongxia Xia, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 6, pp. 1175-1188
Closed Access | Times Cited: 4
MCU genetically altered mice suggest how mitochondrial Ca2+ regulates metabolism
Jiuzhou Huo, Jeffery D. Molkentin
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 10, pp. 918-928
Closed Access | Times Cited: 4
Advances in myocardial energy metabolism: metabolic remodeling in heart failure and beyond
Qiuyu Sun, Qutuba G. Karwi, Nathan Wong, et al.
Cardiovascular Research (2024)
Open Access | Times Cited: 4
Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives
Elina Khattab, Michaelia Kyriakou, Elena Leonidou, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 1, pp. 134-134
Open Access
Targeting aldose reductase using natural African compounds as promising agents for managing diabetic complications
Miriam E. L. Gakpey, Shadrack A. Aidoo, Toheeb A. Jumah, et al.
Frontiers in Bioinformatics (2025) Vol. 5
Open Access
Investigation of Aldose Reductase Inhibitors: Implications for Therapeutic Targets in Diabetic Retinopathy
Behzad Sani, Saheem Ahmad, Hiba Adnan Aziz Abu Omaima, et al.
Journal of Molecular Structure (2025), pp. 142004-142004
Closed Access
The Quest for Understanding Diabetic Cardiomyopathy
Anuradha Lala, Robert J. Mentz, Carlos G. Santos‐Gallego
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 2, pp. 149-151
Closed Access | Times Cited: 3
“Emerging clinical approaches in diabetic cardiomyopathy: insights from clinical trials and future directions”
Murali Krishna Moka, D K Sriram, Melvin George
Acta Diabetologica (2024)
Closed Access | Times Cited: 3
Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy
Peter Galis, Linda Bartosova, Veronika Farkašová, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 2
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019-2023 update of the patent literature.
Bianca Laura Bernardoni, Ilaria D’Agostino, Fabio Scianò, et al.
Expert Opinion on Therapeutic Patents (2024)
Closed Access | Times Cited: 2
Chinese herbal medicine and active ingredients for diabetic cardiomyopathy: molecular mechanisms regulating endoplasmic reticulum stress
Lianjun Ao, Zhengtao Chen, Jiacheng Yin, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
The latest emerging drugs for the treatment of diabetic cardiomyopathy
Minghao Li, Lin Liu, Chunyu Zhang, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 6, pp. 641-654
Closed Access | Times Cited: 1
Heart Failure: A Deficiency of Energy—A Path Yet to Discover and Walk
Ioannis Paraskevaidis, Christos Kourek, Dimitrios Farmakis, et al.
Biomedicines (2024) Vol. 12, Iss. 11, pp. 2589-2589
Open Access | Times Cited: 1
Key Therapeutic Targets to Treat Hyperglycemia-Induced Atherosclerosis Analyzed Using a Petri Net-Based Model
Agnieszka Rybarczyk, Dorota Formanowicz, Piotr Formanowicz
Metabolites (2023) Vol. 13, Iss. 12, pp. 1191-1191
Open Access | Times Cited: 2
Linking Fatty Acid Metabolism to Diabetic Cardiomyopathy: The Role of Mitochondrial Dysfunction and Immune Microenvironment Alterations, a Bioinformatics Approach
Tingjuan Ni, Xingxiao Huang, Sunlei Pan, et al.
Research Square (Research Square) (2024)
Open Access
News in cardiovascular pharmacotherapy from the ACC.24 Meeting
Ricardo Caballero, Eva Delpón, Juan Tamargo
European Heart Journal - Cardiovascular Pharmacotherapy (2024) Vol. 10, Iss. 4, pp. 272-277
Open Access
Intermedin Alleviates Diabetic Cardiomyopathy by Up-Regulating CPT-1β through Activation of the Phosphatidyl Inositol 3 Kinase/Protein Kinase B Signaling Pathway
Jie Zhao, Ling Han, Ya-Rong Zhang, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 9, pp. 1204-1204
Open Access
Page 1

Scroll to top